当前位置:循环首页>正文

[ESH2013]ARB类药物的若干争议——Domenic A. Sica教授专访

作者:  D.A.Sica   日期:2013/6/26 19:26:40

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

要想明确ARBs与癌症风险之间的关系,需要大量的具有效力的个体及集体研究对其进行充分的评估。对所有相关研究的分析显示,似乎ARBs与癌症之间真的没有相关性。有数据提示,ARBs与ACEI类药物联用可能会使癌症风险轻度增加。但这需要考虑以下两个问题,一个是生物学上的合理性,另一个是恶性肿瘤发生的时间过程。人们暴露在某种药物下的时间经常不足以使其发生生物学上导致恶性肿瘤的作用。我们目前只是简单地发现了现有的恶性肿瘤。另一个需要考虑的问题是药物的暴露时间。如果暴露时间足够长,ACEI以及ARBs能够使患者活得更长,因此,也就时我们有更多的时间来发现恶性肿瘤。

  <International Circulation>: ARBs have long been considered beneficial for diabetic nephropathy. How should we properly use ARBs in hypertensive patients with diabetic nephropathy?

  Prof. Sica: We should dose according to the package guidelines up to the top-end dose recommended which is 300mg irbesartan or 100mg losartan. They should not be used as primary therapy at the exclusion of other drugs to lower blood pressure i.e. the drugs themselves have but a modest effect in blood pressure reduction. A very important component of therapy is blood pressure reduction so these drugs have to be accompanied by other appropriate drugs, be they diuretics, calcium channel blockers and drugs of a similar ilk. But you have to get the blood pressure to goal most importantly. If the question asked is, is it better to give the drug and not control blood pressure, then the answer is no. The drug is only as good as its blood pressure reduction and then it confers additional benefits from there. The absence of blood pressure reduction with these drugs is problematic and if it is not reducing pressure then that is where most attention needs to be paid.

  《国际循环》:ARBs有益于糖尿病肾病,在合并糖尿病肾病的患者中,我们应该如何正确使用ARBs?

  Sica教授:在合并糖尿病肾病的患者中,我们应该根据指南来应用ARBs。目前指南推荐的厄贝沙坦及氯沙坦的最大剂量分别是300 mg和100 mg。应用时应与其他具有适度降压效应的其他药物联用。治疗的重要目的是降低血压,因此这些药物应该与利尿剂、钙离子拮抗剂等其他适当的药物联用。但必须使血压达标,这一点是最重要的。如果问题时是否给ARB药物要优先于血压控制,答案是否定的。ARBs的降压作用有限,在降压作用之外,为患者带来额外获益。不关注降压药物的降压作用是有问题的;只有在满足降压目标之后,才应关注其额外获益。

  <International Circulation>: In the treatment of hypertension, compared with free combination therapy, what are the advantages of a single pill combination?

  Prof. Sica: The advantages of single pill combinations are generally that compliance rates improve slightly and it compels the physician to be more aggressive in management where therapeutic inertia is not uncommon for treating physicians. Two medicines in one pill gets people more drugs at the same time and is a no-brainer you could say, i.e. it becomes easier. Starting with one drug and then waiting a period of time before adding a second drug becomes a problem, so the availability of these drugs makes it easier to start two drugs when they are supposed to be started rather than writing two separate prescriptions.

  《国际循环》:治疗高血压时,与自由联合治疗相比,单片复方制剂的优势有哪些?

  Sica教授:单片复方制剂的优势主要是依从性略高,有助于医生更积极地进行高血压管理,不易发生治疗惰性问题。将两种药物融在一片制剂中能使患者每次同时服用更多的药物,使患者服药更简便。先应用一种药物,然后等一段时间在加用第二种药物,这种服药方法非常不方便。而与开具两个单独的处方相比,单片复方制剂则使两种药物同时治疗更为容易和方便。

上一页  [1]  [2]  [3]  

版面编辑:白靖



高血压ARB类药物ARBs心肌梗死ACEI

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530